You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 858 TILKine-2: a novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
858 TILKine-2: a novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021303025
Dec 202156016
Jan 202264025
Feb 202267024
Mar 2022106016
Apr 2022120013
May 2022120027
Jun 20222407
Jul 20222207
Aug 20227409
Sep 202224010
Oct 202260014
Nov 202280011
Dec 20223202
Jan 20232607
Feb 20233405
Mar 20236609
Apr 202350010
May 20233006
Jun 20232402
Jul 20231408
Aug 20233802
Sep 2023802
Oct 2023118012
Nov 20234805
Dec 20238404
Jan 20242201
Feb 20244005
Mar 20244205
Apr 20242403
May 20244209
Jun 20241602
Jul 20241602
Aug 20242604
Sep 20243003
Total19500312